Tuesday, October 6, 2026

Interrogation of Lundin Execs for Crimes Against Humanity and Environment in South Sudan

Terry Swartzberg

October 20, 2018

South Sudan oil contamination. Photo by: Courtesy German NGO Sign of Hope.
MUNICH, Germany (ViaNews) - “Lundin Petroleum’s chief executive and chairman are set to be charged with aggravated crimes against human rights over the Swedish oil company’s role in causing thousands of deaths in South Sudan,” states the report published in the October 18th edition of the Financial Times. These crimes were allegedly committed in the course of Lundin’s exploration for oil in what is now South Sudan. This exploration is said to have been accompanied by widespread “economic cleansing”, in which murder and rape were allegedly used to drive nearly 200,000 people from their homes, thus clearing the way for the unimpeded exploration and production of oil. [caption id="attachment_5410" align="aligncenter" width="950"]South Sudan oil contamination. Photo by: Courtesy German NGO Sign of Hope. South Sudan oil contamination. Photo by: Courtesy German NGO Sign of Hope.[/caption] Should the Lundin execs be indicted and then convicted for these crimes against humanity, they would be most probably sent to jail for life. Of greater impact would be the case’s precedent-setting nature. Lundin’s activities in South Sudan pale in scope and severity to those undertaken by China National Petroleum, Malaysia’s Petronas, and India’s ONGC Videsh. According to the study compiled by German NGO Sign of Hope, Petronas alone is responsible for the contamination of water consumed by more than 600,000 South Sudanese and by their livestock. Poisoned with a witches’ brew of lead, barium, salts and other toxic materials, this water is also being used to irrigate fields. The results: large-scale swathes of South Sudan have become inhabitable. And the ensuing hunger and thirst are joining with the fear generated by the oil-fueled civil war in causing millions of South Sudanese to flee for their lives.

Categories

Tags

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com